MedTrace Logo

Immunotherapy of Melanoma Patients

NCT00112216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-04-24

No results posted yet for this study

Summary

The purpose of this study is to test whether vaccination with antigenic peptides induces an immune response in the vaccine site sentinel lymph node of patients with microscopically detectable lymph node melanoma metastases.

Conditions

Interventions

BIOLOGICAL

Melan-A analog peptide

BIOLOGICAL

FluMa peptide

BIOLOGICAL

Mage-A10 peptide

BIOLOGICAL

SB AS-2 adjuvant

BIOLOGICAL

Montanide adjuvant

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Vaudois

    lead OTHER

Principal Investigators

  • Daniel Speiser, MD · Ludwig Institute for Cancer Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-05-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00112216 on ClinicalTrials.gov